India joins weight-loss drug race, but affordability remains a concern | Industry News
 According to data from market research firm Pharmarack, the drugs that mimic GLP-1, called semaglutide, expanded from ₹527 crore in annual revenue in March 2025 (trailing twelve months) to around ₹1,600 crore in March 2026 — more than tripling in value in a year. The trigger has been a flood of branded semaglutide…